Topics

Articles

How current frameworks influence coverage decisions and pricing negotiations.

The Evolving Value Assessment Landscape in the US

The products, cloud revenue management solution provider says, are aimed at addressing supply chain challenges.

Model N’s Latest Enhancements Address Duplicate Discounts, Global Tender Management

Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.

Mark Cuban's Cost Plus Drug Co. Expands to Offer J&J Brand-Name Medications

How various factors are affecting the amount of funds allocated to healthcare.

Assessing Drug Pricing in Europe

Pharma Commerce provides a look into a few of the conference’s highlights. 

PAP 2023: Where Patient Access and Adherence Meet Regulatory Policy

AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles. 

PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023

AmerisourceBergen exec dives into the shift in Medicare Part D patient requirements.

PAP 2023: Corey Ford Discusses Part D Requirements at Access PAP 2023

New Pharma Commerce column addresses the relevance of pricing.

Introducing Value & Access 

Semiannual update includes better revenue forecasting and state reporting

Model N Updates Its Revenue-Management Solution for Commercial Pharma Practices

Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies

Market Access and Pricing